Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 648

1.

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H.

Cancer Cell. 2017 Feb 13;31(2):225-239. doi: 10.1016/j.ccell.2017.01.005.

PMID:
28196595
2.

Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.

Pelosof L, Ahn C, Gao A, Horn L, Madrigales A, Cox J, McGavic D, Minna JD, Gazdar AF, Schiller J.

J Natl Cancer Inst. 2017 Jan 28;109(7). pii: djw295. doi: 10.1093/jnci/djw295.

PMID:
28132018
3.

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.

Tagal V, Wei S, Zhang W, Brekken RA, Posner BA, Peyton M, Girard L, Hwang T, Wheeler DA, Minna JD, White MA, Gazdar AF, Roth MG.

Nat Commun. 2017 Jan 19;8:14098. doi: 10.1038/ncomms14098.

4.

MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, Berrett KC, Mosbruger TL, Wang J, Kohan JL, Salama ME, Witt BL, Peifer M, Thomas RK, Gertz J, Johnson JE, Gazdar AF, Wechsler-Reya RJ, Sos ML, Oliver TG.

Cancer Cell. 2017 Feb 13;31(2):270-285. doi: 10.1016/j.ccell.2016.12.005.

PMID:
28089889
5.

Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.

Çeliktaş M, Tanaka I, Chandra Tripathi S, Fahrmann JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon D, Dennison JB, Ostrin EJ, Wang H, Behrens C, Do KA, Gazdar AF, Hanash SM, Taguchi A.

J Natl Cancer Inst. 2016 Dec 29;109(3). pii: djw231. doi: 10.1093/jnci/djw231.

PMID:
28034896
6.

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.

Zhang YA, Zhou Y, Luo X, Song K, Ma X, Sathe A, Girard L, Xiao G, Gazdar AF.

EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040.

7.

ZEB1 drives epithelial-to-mesenchymal transition in lung cancer.

Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, Girard L, Behrens C, Wistuba II, Gazdar AF, Hayward NK, Minna JD.

J Clin Invest. 2016 Sep 1;126(9):3219-35. doi: 10.1172/JCI76725.

8.

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.

Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, Girard L, Minna JD, Gazdar AF, Cobb MH, Johnson JE.

Cell Rep. 2016 Aug 2;16(5):1259-72. doi: 10.1016/j.celrep.2016.06.081.

9.

An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.

Girard L, Rodriguez-Canales J, Behrens C, Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD, Wistuba II, Minna JD, Gazdar AF.

Clin Cancer Res. 2016 Oct 1;22(19):4880-4889.

PMID:
27354471
10.

Correction: "From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers".

Gazdar AF, Hirsch FR, Minna JD.

J Thorac Oncol. 2016 Jul;11(7):e88-9. doi: 10.1016/j.jtho.2016.04.003. No abstract available.

PMID:
27339412
11.

A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H, Xing C, Kittler R, Milchgrub S, Castrillon DH, Davidson HL, Reynolds CP, Lam WL, Lea J, Gazdar AF.

Oncotarget. 2016 Jun 10. doi: 10.18632/oncotarget.9929. [Epub ahead of print]

12.

Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.

Kim DW, Wu N, Kim YC, Cheng PF, Basom R, Kim D, Dunn CT, Lee AY, Kim K, Lee CS, Singh A, Gazdar AF, Harris CR, Eisenman RN, Park KS, MacPherson D.

Genes Dev. 2016 Jun 1;30(11):1289-99. doi: 10.1101/gad.279307.116.

13.

Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer.

Gazdar AF, Minna JD.

J Natl Cancer Inst. 2016 May 31;108(10). pii: djw119. doi: 10.1093/jnci/djw119. No abstract available.

PMID:
27247352
14.

ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers.

Wang YW, Ma X, Zhang YA, Wang MJ, Yatabe Y, Lam S, Girard L, Chen JY, Gazdar AF.

J Thorac Oncol. 2016 Sep;11(9):1469-81. doi: 10.1016/j.jtho.2016.05.010.

PMID:
27234602
15.

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.

Frink RE, Peyton M, Schiller JH, Gazdar AF, Shay JW, Minna JD.

Oncotarget. 2016 May 31;7(22):31639-51. doi: 10.18632/oncotarget.9335.

16.

Inhibiting the Jumonji family: a potential new clinical approach to targeting aberrant epigenetic mechanisms.

Martinez ED, Gazdar AF.

Epigenomics. 2016 Mar;8(3):313-6. doi: 10.2217/epi.15.115. No abstract available.

PMID:
26918824
17.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Review. No abstract available.

PMID:
26829312
18.

Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.

Zhang YA, Ma X, Sathe A, Fujimoto J, Wistuba II, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, Larsen JE, Girard L, Liu X, Song K, Behrens C, Kalhor N, Xie Y, Zhang MQ, Minna JD, Gazdar AF.

J Thorac Oncol. 2016 Mar;11(3):346-60. doi: 10.1016/j.jtho.2015.11.004.

PMID:
26725182
19.

From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.

Gazdar AF, Hirsch FR, Minna JD.

J Thorac Oncol. 2016 Mar;11(3):287-99. doi: 10.1016/j.jtho.2015.10.009. Review.

20.

Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma.

Soh J, Toyooka S, Matsuo K, Yamamoto H, Wistuba II, Lam S, Fong KM, Gazdar AF, Miyoshi S.

Oncol Lett. 2015 Sep;10(3):1775-1782.

Items per page

Supplemental Content

Loading ...
Support Center